Human epidermal growth factor receptor 2 (HER2) amplification or overexpression presents in approximately 15%–20% of breast cancer and correlates with more aggressive clinical phenotype, increased metastatic potential, and shorter survival (1). Here, ERBB2 is linked to breast carcinoma.